The voluntary recall stems from infections from a single donor lot, according to a news release. Before release, samples from the lot had tested negative for tuberculosis.
Aziyo Biologics is cooperating and investigating with the FDA and CDC, the company said. Shipping for all viable bone matrix products from all donor lots was suspended. Aziyo Biologics is also working to notify patients who received bone matrix products from the affected donor lot.
Two years ago, Aziyo Biologics recalled another bone repair product, FiberCel, after multiple patients tested positive for tuberculosis.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
